Nuclera

Cambridge, United Kingdom · Founded 2013 · Privately Held (backing)

Developer of a protein prototyping system designed to accelerate drug discovery workflows. Nuclera is based in Cambridge, United Kingdom and was founded in 2013. It was valued at $155 million at its Series B in Jul 2022, the last priced event on record. It has raised $166 million across 9 recorded rounds; the latest was an $87 million Series C in Jan 2026.

PMV mark · valuation
$154.5M
Oct 2026
Priced at
its Series B
Jul 2022
Total raised
$166.1M
Last round
Later Stage VC (Series C)
Jan 2026

Who backs Nuclera?

22 investors
InvestorType
Innovate UKOther
Tech Nation GroupOther
Puhua CapitalOther
British Business BankOther
Future Planet CapitalVenture capital
Verve VenturesVenture capital
Amadeus Capital PartnersVenture capital
Meltwind Advisory—
Accelerate Cambridge—
Jonathan Milner—
+ 12 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Nuclera investors

22 investors are on record for Nuclera, including Innovate UK, Tech Nation Group, Puhua Capital and British Business Bank. By type, the record holds 4 venture capital firms and 1 asset manager. The Series C in Jan 2026 drew 11 investors.

Free account
More of Nuclera with a free account
  • ·Post-money valuations for 2 rounds
  • ·The complete investor list: 22 names
  • ·Watch Nuclera: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 22 firms already write checks for companies like Nuclera. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View